Uterine Atony With Hemorrhage Clinical Trial
Official title:
Serum Antimullerian Hormone Levels in Patients Who Underwent Hayman Suture for Uterine Atony During Cesarean Section
NCT number | NCT03930407 |
Other study ID # | AYSUAKCA1 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 15, 2019 |
Est. completion date | June 15, 2019 |
From patient charts we will review patients who had undergone cesarean section within the last 6 months and identify those who received a The Hayman uterine compression suture for uterine atony. We will also select patients who delivered a baby without recieving a Hayman suture to create a control group. Patietns will be grouped as Hayman Group if they recevied a Hayman suture during C/S and control group if thay had not recevied a Hayman suture. We will then check patient charts for post-cesarean outpatient clinic visit and select those who received ovarian reserve evaluation via hormones and antral follicle count during the visits. Finally, we are planning to investigate any correlation between Hayman suture and ovarian dysfunction.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | June 15, 2019 |
Est. primary completion date | June 10, 2019 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - age 18- 40 years - no systemic or endocrine diseases - patients who had uterine artery ligation due to atony - healthy postpartum patients as controls Exclusion Criteria: - patients with Polyctsitic over syndrome - Pregnancy with IVF or oocyte donation - Obese patients - patients with previous/present endometriosis |
Country | Name | City | State |
---|---|---|---|
Turkey | Department of Obstetrics and Gynecology, University of Health Sciences, Faculty of Medicine, Kanuni Sultan Suleyman Hospital, | Istanbul | Please Enter The State Or Province |
Lead Sponsor | Collaborator |
---|---|
Kanuni Sultan Suleyman Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anti-mullerian hormone level from baseline (precesarean) to post-cesarean | ng/dl | Before cesarean section and at any follow-up visit within 6 months of cesarean section | |
Primary | Change in follicle stimulating hormone level from baseline (precesarean) to post-cesarean | IU/L | Before cesarean section and at any follow-up visit within 6 months of cesarean section | |
Primary | Change in luteinizing hormone level from baseline (precesarean) to post-cesarean | mU/mL | Before cesarean section and at any follow-up visit within 6 months of cesarean section | |
Secondary | Antral follicle count in the two study groups | number | At any follow-up visit within 6 months of cesarean section |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06219538 -
DAISY Uterine Drain Device Evaluation
|
N/A | |
Completed |
NCT03959436 -
Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery
|
||
Completed |
NCT03867383 -
Calcium Chloride for Prevention of Uterine Atony During Cesarean
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03361124 -
Oxytocin Dosing at Planned Cesarean Section and Anemia
|
Phase 4 | |
Completed |
NCT03904446 -
Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients
|
Phase 4 | |
Completed |
NCT06353074 -
Uterine Preservation With Acar's Atony Suture for Postpartum Uterine Hemorrhage
|
||
Completed |
NCT05027048 -
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
|
Phase 3 | |
Recruiting |
NCT04833556 -
Perioperative Outcomes of Postpartum Hemorrhage in Patients Undergoing Cesarean Delivery
|